Triple
T23399617
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | bapineuzumab |
E559467
|
entity |
| Predicate | instanceOf |
P0
|
FINISHED |
| Object | Alzheimer’s disease therapy candidate |
C7048
|
CONCEPT FINISHED |
How this triple was built (1 step)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
CD
Concept disambiguation
gpt-5-mini-2025-08-07
Target class: Alzheimer’s disease therapy candidate Context triple: [bapineuzumab, instanceOf, Alzheimer’s disease therapy candidate]
-
A.
Alzheimer’s disease clinical trial
An Alzheimer’s disease clinical trial is a structured research study designed to evaluate the safety, tolerability, and effectiveness of investigational interventions aimed at preventing, slowing, or treating cognitive and functional decline associated with Alzheimer’s disease in human participants.
-
B.
Alzheimer’s disease drug
chosen
An Alzheimer’s disease drug is a pharmacological agent designed to prevent, slow, or alleviate the cognitive and functional decline associated with Alzheimer’s pathology, typically by targeting amyloid, tau, neurotransmitter systems, or related neurodegenerative mechanisms.
-
C.
transthyretin synthesis inhibitor
A transthyretin synthesis inhibitor is a drug that reduces the production of transthyretin protein, thereby limiting the formation and deposition of amyloid fibrils associated with transthyretin-mediated amyloidosis.
-
D.
oral suspension formulation of edaravone
An oral suspension formulation of edaravone is a liquid dosage form in which edaravone is dispersed in a suitable vehicle to enable accurate, stable, and patient-friendly oral administration for therapeutic use.
-
E.
RNA interference-based therapy
RNA interference-based therapy is a treatment approach that uses small RNA molecules to selectively silence disease-related genes by degrading their corresponding messenger RNA.
- F. None of above.
Provenance (1 batch)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e24549610c8190a069d6411ce5f661 |
completed | April 17, 2026, 2:35 p.m. |
Created at: April 17, 2026, 5:37 p.m.